DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR RELISTOR
➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
All Clinical Trials for Relistor
| Trial ID |
Title |
Status |
Sponsor |
Phase |
Start Date |
Summary |
| NCT00804141 ↗ |
Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation |
Completed |
Pfizer |
Phase 3 |
2008-12-01 |
This is a one-year study to evaluate the long-term safety and tolerability of the
subcutaneous (just under the skin) injection form of MOA-728 for the treatment of
opioid-induced constipation in subjects with nonmalignant pain. The study consists of a 2
week screening period, a 48 week open-label treatment period and a 2 week follow-up period.
Subjects will need to agree to self-administer subcutaneous injections, complete daily
diaries, and check-in via a daily telephone call during that year-long period.
|
| NCT00804141 ↗ |
Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation |
Completed |
Valeant Pharmaceuticals International, Inc. |
Phase 3 |
2008-12-01 |
This is a one-year study to evaluate the long-term safety and tolerability of the
subcutaneous (just under the skin) injection form of MOA-728 for the treatment of
opioid-induced constipation in subjects with nonmalignant pain. The study consists of a 2
week screening period, a 48 week open-label treatment period and a 2 week follow-up period.
Subjects will need to agree to self-administer subcutaneous injections, complete daily
diaries, and check-in via a daily telephone call during that year-long period.
|
| NCT00949377 ↗ |
Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department? |
Withdrawn |
Wyeth is now a wholly owned subsidiary of Pfizer |
Phase 4 |
2009-09-01 |
The investigators want to prove that people WITHOUT advanced cancer who are taking opioid
medications (for problems like back pain) can receive methylnaltrexone (MNTX) safely. Since
the FDA has only approved MNTX for advanced cancer patients, the investigators' research is
investigating how MNTX can work for NON-cancer patients. This research is being conducted to
prove that MNTX can work for non-cancer patients with opioid related constipation.
|
| >Trial ID |
>Title |
>Status |
>Phase |
>Start Date |
>Summary |
Clinical Trial Conditions for Relistor
Condition Name
| Condition Name for Relistor |
| Intervention |
Trials |
| Constipation |
4 |
| Pharyngeal Dysfunction |
2 |
| Gastric Motility Disorder |
1 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Condition MeSH
| Condition MeSH for Relistor |
| Intervention |
Trials |
| Constipation |
7 |
| Coronary Artery Disease |
1 |
| Chronic Pain |
1 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Locations for Relistor
Trials by Country
| Trials by Country for Relistor |
| Location |
Trials |
| United States |
40 |
| Canada |
8 |
| Korea, Republic of |
3 |
| Spain |
2 |
| Colombia |
2 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Trials by US State
| Trials by US State for Relistor |
| Location |
Trials |
| Minnesota |
2 |
| Massachusetts |
2 |
| Florida |
2 |
| Washington |
2 |
| Pennsylvania |
2 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Progress for Relistor
Clinical Trial Phase
| Clinical Trial Phase for Relistor |
| Clinical Trial Phase |
Trials |
| Phase 4 |
9 |
| Phase 3 |
3 |
| Phase 2 |
1 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Status
| Clinical Trial Status for Relistor |
| Clinical Trial Phase |
Trials |
| Completed |
7 |
| Not yet recruiting |
4 |
| Withdrawn |
2 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Sponsors for Relistor
Sponsor Name
| Sponsor Name for Relistor |
| Sponsor |
Trials |
| Wyeth is now a wholly owned subsidiary of Pfizer |
4 |
| Region Örebro County |
2 |
| University of Florida |
1 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Sponsor Type
| Sponsor Type for Relistor |
| Sponsor |
Trials |
| Other |
17 |
| Industry |
6 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
